Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study

Main Article Content

AB Gottlieb
P Gisondi
J Eells
L Peterson
A Kavanaugh


Psoriasis, Certolizumab


Abstract not available.


1. Certolizumab Pegol Prescribing Information. Available at www.fda.gov/drugs
2. Certolizumab Pegol Summary of Product Characteristics. Available at www.ema.europa.eu/ema
3. van der Heijde D. RMD Open 2018;4:e000582
4. van der Heijde D. EULAR 2018
5. Gordon K. EADV 2019;870
6. Gordon K. EADV 2019;1556
7. Gordon K. AAD 2019
8. Coates LC. Ann Rheum Dis 2010;69:48–53

Most read articles by the same author(s)

1 2 > >>